Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05384262 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
A Phase 1 study of Dyslipidemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 183
- Enrollment target
- 3
- Study locations
NCT05384262: Completed Phase 1 study of Dyslipidemia, sponsored by AstraZeneca.
NCT05384262 is a Phase 1 study of Dyslipidemia that has completed, run by AstraZeneca. The registered enrollment target is 183 participants, below the 358-participant average among 40 other Dyslipidemia trials with a reported enrollment target (49% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05384262, a Phase 1 study of Dyslipidemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 183 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels. This study will consist of two parts (Parts A and B). 56 subjects have been planned for Part A and 141 subjects for Part B. Additional subjects may be included for the optional cohorts depending upon emerging data.
Primary Outcome
The safety and tolerability of AZD0780 following oral administration of single ascending doses (Part A) and multiple ascending doses (Part B) will be assessed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD0780
Study Locations (3)
California
- Research Site - Glendale
Maryland
- Research Site - Brooklyn
Other
- Research Site - Harrow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2022-05-18 |
| Est. Completion | 2024-06-14 |
| Phase | Phase 1 |
What the finished NCT05384262 record still lists
NCT05384262 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 358-participant average among 40 other Dyslipidemia trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05384262 reports a single indexed study location in California, Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT05384262 about?
NCT05384262 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects". This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels. This study will consist of two parts (Parts...
What is the current status of trial NCT05384262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2022-05-18. Estimated completion is 2024-06-14.
What conditions does trial NCT05384262 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT05384262?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).
Who is sponsoring clinical trial NCT05384262?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05384262 being conducted?
This trial has 3 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05384262's enrollment target sits among peer trials
183 16th of 40 higher than 25 of 40 other Dyslipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
RECRUITING · Phase 1
-
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
COMPLETED · Phase 1
-
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
COMPLETED · Phase 1
-
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
COMPLETED · Phase 1
-
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
COMPLETED · Phase 1
-
Effects of Niacin On Fatty Acid Trapping
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI